Brian M. Slomovitz, Bradley J. Monk, Krishnansu Sujata Tewari, Noelle Cloven, Alberto Farolfi, Annamaria Ferrero, David Cibula, Coraline Dubot, Lisa Barraclough, Lorena Fariñas-Madrid, Ignacio Casarini, Andreia Cristina de Melo, Fernando Contreras Mejia, Sudeep Gupta, Jung-Yun Lee, Kosei Hasegawa, Zhou Yu, Cumhur Tekin, Ved Desai, Toon Van Gorp. "TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase 3, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical cancer.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps5628